Clinuvel Pharmaceuticals Limited Share Price Deutsche Boerse AG
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.400 EUR | +8.47% |
|
+2.40% | -8.57% |
| Market Cap | 52Cr 36Cr 32Cr 29Cr 27Cr 51Cr 3.49TCr 350.2Cr 137.28Cr 1.71TCr 135.74Cr 132.78Cr 5.88TCr | P/E 2026 * |
14.4x | P/E 2027 * | 13.5x |
|---|---|---|---|---|---|
| Enterprise Value | 26Cr 18Cr 16Cr 15Cr 14Cr 26Cr 1.77TCr 178.14Cr 70Cr 867.63Cr 69Cr 68Cr 2.99TCr | EV / Sales 2026 * |
2.64x | EV / Sales 2027 * | 2.19x |
| Free-Float |
83.79% | Yield 2026 * |
0.6% | Yield 2027 * | 0.78% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | +8.47% | ||
| 1 week | +2.40% | ||
| Current month | +7.56% | ||
| 1 month | +6.67% | ||
| 3 months | +12.48% | ||
| 6 months | -8.57% | ||
| Current year | -8.57% |
| 1 week | 5.9 |  | 6.4 |
| 1 month | 5.7 | | 6.4 |
| Current year | 5.1 | | 7.39 |
| 1 year | 5.1 | | 7.68 |
| 3 years | 4.8 | | 12.68 |
| 5 years | 4.8 | | 27 |
| 10 years | 3.12 | | 27 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +8.47% | +2.40% | - | - | 35Cr | |
| -0.67% | +1.37% | +23.89% | -7.04% | 6.88TCr | |
| -0.54% | +1.02% | +36.12% | +189.96% | 5.21TCr | |
| -3.65% | +34.50% | +34.50% | +34.50% | 4.35TCr | |
| -0.54% | -0.98% | -52.31% | -54.42% | 4.12TCr | |
| -2.93% | -4.34% | +59.97% | -27.21% | 3.04TCr | |
| -3.77% | -11.22% | +90.31% | -52.32% | 2.45TCr | |
| -1.36% | +1.24% | +70.42% | +80.67% | 2.34TCr | |
| +3.99% | +3.82% | +3.87% | +196.00% | 1.98TCr | |
| +0.26% | +0.39% | +70.47% | +126.52% | 1.66TCr | |
| Average | -0.09% | -2.12% | +37.47% | +54.07% | 3.56TCr | |
| Weighted average by Cap. | -1.21% | -1.42% | +30.60% | +45.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.95Cr 6.96Cr 6.1Cr 5.64Cr 5.19Cr 9.79Cr 671.41Cr 67Cr 26Cr 328.51Cr 26Cr 26Cr 1.13TCr | 11Cr 7.38Cr 6.46Cr 5.98Cr 5.5Cr 10Cr 711.2Cr 71Cr 28Cr 347.98Cr 28Cr 27Cr 1.2TCr |
| Net income | 3.6Cr 2.52Cr 2.21Cr 2.04Cr 1.88Cr 3.54Cr 242.79Cr 24Cr 9.56Cr 118.8Cr 9.45Cr 9.25Cr 409.29Cr | 3.82Cr 2.67Cr 2.34Cr 2.17Cr 1.99Cr 3.76Cr 257.87Cr 26Cr 10Cr 126.17Cr 10Cr 9.82Cr 434.7Cr |
| Net Debt | -25Cr -18Cr -16Cr -14Cr -13Cr -25Cr -1.71TCr -172.05Cr -67Cr -837.95Cr -67Cr -65Cr -2.89TCr | -29Cr -20Cr -18Cr -16Cr -15Cr -28Cr -1.93TCr -193.98Cr -76Cr -944.75Cr -75Cr -74Cr -3.25TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/26/20 | €6.400 | +8.47% | 338 |
| 17/26/17 | €5.900 | -1.37% | 358 |
| 16/26/16 | €5.982 | -4.29% | 0 |
| 15/26/15 | €6.250 | 0.00% | 0 |
| 14/26/14 | €6.250 | 0.00% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- UR9 Stock
Select your edition
All financial news and data tailored to specific country editions
